5ZV3

Crystal structure of human anti-tau antibody CBTAU-28.1 in complex with its tau peptide


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.09 Å
  • R-Value Free: 0.251 
  • R-Value Work: 0.187 
  • R-Value Observed: 0.191 

wwPDB Validation 3D Report Full Report



Literature

A common antigenic motif recognized by naturally occurring human VH5-51/VL4-1 anti-tau antibodies with distinct functionalities.

Apetri, A.Crespo, R.Juraszek, J.Pascual, G.Janson, R.Zhu, X.Zhang, H.Keogh, E.Holland, T.Wadia, J.Verveen, H.Siregar, B.Mrosek, M.Taggenbrock, R.Ameijde, J.Inganas, H.van Winsen, M.Koldijk, M.H.Zuijdgeest, D.Borgers, M.Dockx, K.Stoop, E.J.M.Yu, W.Brinkman-van der Linden, E.C.Ummenthum, K.van Kolen, K.Mercken, M.Steinbacher, S.de Marco, D.Hoozemans, J.J.Wilson, I.A.Koudstaal, W.Goudsmit, J.

(2018) Acta Neuropathol Commun 6: 43-43

  • DOI: 10.1186/s40478-018-0543-z
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • Misfolding and aggregation of tau protein are closely associated with the onset and progression of Alzheimer's Disease (AD). By interrogating IgG + memory B cells from asymptomatic donors with tau peptides, we have identified two somatica ...

    Misfolding and aggregation of tau protein are closely associated with the onset and progression of Alzheimer's Disease (AD). By interrogating IgG + memory B cells from asymptomatic donors with tau peptides, we have identified two somatically mutated V H 5-51/V L 4-1 antibodies. One of these, CBTAU-27.1, binds to the aggregation motif in the R3 repeat domain and blocks the aggregation of tau into paired helical filaments (PHFs) by sequestering monomeric tau. The other, CBTAU-28.1, binds to the N-terminal insert region and inhibits the spreading of tau seeds and mediates the uptake of tau aggregates into microglia by binding PHFs. Crystal structures revealed that the combination of V H 5-51 and V L 4-1 recognizes a common Pro-X n -Lys motif driven by germline-encoded hotspot interactions while the specificity and thereby functionality of the antibodies are defined by the CDR3 regions. Affinity improvement led to improvement in functionality, identifying their epitopes as new targets for therapy and prevention of AD.


    Organizational Affiliation

    Department of Neurology, Amsterdam Neuroscience, Academic Medical Center, Meidreefberg 9, 1105, AZ, Amsterdam, the Netherlands.



Macromolecules
  • Find similar proteins by: Sequence   |   Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Peptide from Microtubule-associated protein tau
A
20Homo sapiensMutation(s): 0 
Gene Names: MAPTMAPTLMTBT1TAU
Find proteins for P10636 (Homo sapiens)
Go to UniProtKB:  P10636
NIH Common Fund Data Resources
PHAROS  P10636
Protein Feature View
  • Reference Sequence

Find similar proteins by: Sequence  |  Structure

Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
Heavy chain of antibody CBTAU28.1
H
227Homo sapiensMutation(s): 0 
Protein Feature View
  • Reference Sequence

Find similar proteins by: Sequence  |  Structure

Entity ID: 3
MoleculeChainsSequence LengthOrganismDetails
Light chain (kappa) of antibody CBTAU28.1
L
220Homo sapiensMutation(s): 0 
Protein Feature View
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.09 Å
  • R-Value Free: 0.251 
  • R-Value Work: 0.187 
  • R-Value Observed: 0.191 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 77.241α = 90
b = 49.423β = 105.55
c = 61.375γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
HKL-2000data reduction
HKL-2000data scaling
PHASERphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2018-06-20
    Type: Initial release